Introduction {#s1}
============

Adolescent pregnancy is a major public health problem in many developing countries, including Thailand \[[@R01]-[@R03]\]. Recently a national survey reported adolescent birth rate in Thai was 117 per 1,000 deliveries \[[@R02], [@R03]\]. Pregnancy in this vulnerable age group not only increases the risk of adverse pregnancy outcomes, but also negatively influences the quality of their life. Previous study reported that the vast majority of adolescent pregnancy had not intended to become pregnant. In addition, a substantial number of them are unwanted and might be terminated by undergoing an unsafe abortion. Thus, effective contraception is very important in this age group \[[@R01]\].

Several policy statements recommend the long-acting reversible contraception (LARC), including intrauterine devices and subdermal implants, be used as the first-line contraceptive option in adolescent girls and young women \[[@R04]\]. Currently, it seems that only 1-4% of them are utilizing these contraceptive methods. These may be due to that there are several barriers for teens to use LARC, such as lack of method offering, its cost and accessibility. Nowadays, the most frequently used contraceptive methods in adolescents are combined oral contraception (COC) and depot medroxyprogesterone acetate (DMPA) injection \[[@R05]\].

DMPA is an accessible contraception with high efficacy and privacy. However, concerns of weight gain associated with DMPA use can impede contraceptive initiation and can lead to early discontinuation among the users. Weight gain has been reported as the most important reason for contraceptive discontinuation by 40% of adolescents receiving DMPA \[[@R06]\]. Proper counseling prior initiation of the method might improve the perception of weight change and reduce ongoing discontinuation. Several existing evidences demonstrated a significantly increased weight in DMPA users with the prevalence of excessive weight gain up to one-fourth in all age groups \[[@R06]-[@R08]\]. A recent meta-analysis was still inconclusive about an excessive weight gain associated with DMPA use, especially in adolescent girls and young women who still have a physiologic growth with different basal metabolic rate \[[@R9]\].

An excessive weight gain is an important concerning adverse effect among DMPA users that can deter contraceptive initiation and continuation, and the evidences of weight gain in adolescent users were still limited, highlighting the need to explore this point of view. Accordingly, the objective of the present study was to determine the prevalence of excessive weight gain and its associated factors among adolescent girls and young women who used DMPA injection.

Materials and Methods {#s2}
=====================

The protocol of the present retrospective study was approved by the Siriraj Institutional Review Board (COA no. si583/2017). All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

The requirement to obtain written informed consent was waived given the retrospective nature of this study. This retrospective chart review included all young women aged 10 - 24 years who had started using DMPA injection and attended at the Family Planning and Reproductive Medicine Unit, Siriraj Hospital during the study period from January 2010 to June 2016. The exclusion criteria were women who had delivered infant of less than 3 months, had chronic medical disorders affecting bodily metabolism, had concurrent use of other hormonal drugs, had a pregnancy within the study period, and had inadequate data about body weight either at baseline or 6 months after starting DMPA.

Collected data included clinical characteristics and demographic data, such as age, race, marital status, parity, last child delivery, and previous history of hormonal contraceptive use. Body weight of each visit was obtained from the medical record. The weight of all women was measured with a calibrated digital scale at each visit. An excessive weight gain was defined by using a percentage of weight change from baseline that was classified into two subtypes: an early excessive weight gain which was defined as an increasing weight of more than 5% from their baseline weight at 6 months after DMPA initiation, and a later excessive weight gain which was defined as an increasing weight of more than 10% from their baseline weight at 10 months after DMPA initiation \[[@R08]\].

The sample size was calculated based on the prevalence of an early excessive weight gain in adolescent and younger DMPA users of 28.2% \[[@R07]\]; a total of 216 women would be required for an alpha of 0.05 with an absolute precision error of 6%.

STATA statistical software (version 11; StataCorp LLC, College Station, TX, USA) was used to analyze data. Data were presented as mean ± standard deviation (SD), number (n) and percent, or percent and 95% confidence interval (CI) as appropriate. The data were analyzed using Chi-square test or Fisher's exact test for categorical data, and *t*-test or Mann-Whitney U test for continuous data. A regression analysis was performed to compare data between groups. Statistical significance was considered when a P value was less than 0.05.

Results {#s3}
=======

Initially, a total of 1,819 women started DMPA injection during the studying period and met the inclusion criteria, but 1,588 were excluded according to the above mentioned exclusion criteria. Finally, 231 women were recruited in this study ([Fig. 1](#F1){ref-type="fig"}). The clinical characteristics and demographic data of all patients were shown in [Table 1](#T1){ref-type="table"}. They were 20.17 ± 2.64 years of age and 39.8% of them were adolescent. Almost all of them were Thai. Their average body mass index (BMI) was 21.00 ± 3.49 kg/m^2^ and few of them were obese (2.46%). The majority of the patients were married or in union. Of all patients, only 8.23% were nulliparous and nearly 15% had ever used DMPA. The mean body weight of all DMPA users at baseline and at 6 months, 12 months after method initiation were demonstrated in [Figure 2](#F2){ref-type="fig"}.

![Flow of the study. DMPA: depot medroxyprogesterone acetate.](jocmr-11-326-g001){#F1}

###### Baseline Characteristics of 231 DMPA Users

  Characteristics              Total (n = 231), mean ± SD or n (%)   Early weight gainer (n = 28), mean ± SD or n (%)   Non-early weight gainer (n = 203), mean ± SD or n (%)   P
  ---------------------------- ------------------------------------- -------------------------------------------------- ------------------------------------------------------- -------
  Age (years)                  20.17 ± 2.64                          19.67 ± 2.60                                       20.24 ± 2.60                                            0.291
  Adolescent                   92 (39.83)                            13 (46.43)                                         79 (38.92)                                              0.538
  Race                         1.000                                                                                                                                            
    Thai                       219 (94.81)                           28 (100)                                           191 (94.09)                                             
    Burmese                    5 (2.16)                              0 (0)                                              5 (2.46)                                                
    Laos                       6 (2.60)                              0 (0)                                              6 (2.96)                                                
    Cambodian                  1 (0.43)                              0 (0)                                              1 (0.49)                                                
  Married or in-union status   220 (95.24)                           24 (85.71)                                         196 (96.55)                                             0.032
  BMI (kg/m^2^)                21.00 ± 3.49                          21.21 ± 3.41                                       20.98 ± 3.51                                            0.746
  Baseline weight (kg)         52.19 ± 9.46                          52.86 ± 9.48                                       52.10 ± 9.47                                            0.691
  Height (cm)                  157.56 ± 6.30                         157.67 ± 5.71                                      157.54 ± 6.39                                           0.917
  Ever-use DMPA                33 (14.29)                            9 (32.14)                                          24 (11.82)                                              0.008
  Ever-use COC                 118 (51.08)                           14 (50.00)                                         104 (51.23)                                             1.000
  Nulliparous                  19 (8.23)                             7 (25.00)                                          12 (5.91)                                               0.003
  Parity (n = 212)             1.000                                                                                                                                            
    One                        179 (84.43)                           18 (85.71)                                         161 (84.29)                                             
    Two                        30 (14.29)                            3 (14.29)                                          27 (14.14)                                              
    Three or more              0 (0)                                 0 (0)                                              3 (1.57)                                                

Adolescent: person aged 10 - 19 years; BMI: body mass index; DMPA: depot medroxyprogesterone acetate; COC: combined oral contraception. P value \< 0.05 indicates statistical significance.
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Among 231 DMPA users in this study, there were 28 women who had more than a 5% weight gain after 6 months of DMPA use. The prevalence of an early excessive weight gain was 12.1% (95% CI: 7.8 - 16.3). Clinical characteristics and demographic data of 28 women who had more than a 5% weight gain after 6 months of DMPA use and 203 women who had less than a 5% weight gain after 6 months of DMPA use were also shown in [Table 1](#T1){ref-type="table"}. The excessive weight gain group had significant higher proportion of nulliparous, unmarried status and DMPA-ever used history compared to another one. The estimated risk for early excessive weight gain increased in women who were nulliparous (relative risk (RR) 3.71, 95% CI: 1.81 - 7.60), were in unmarried or non-in union status (RR 3.33, 95% CI: 1.39 - 7.94), and had ever used DMPA (RR 2.84, 95% CI: 1.40 - 5.73), as presented in [Table 2](#T2){ref-type="table"}.

###### Estimated Risk of Having Early Excessive Weight Gain in 231 DMPA Users

  Factors                            Relative risk   95% CI        P value
  ---------------------------------- --------------- ------------- ---------
  Unmarried or non-in union status   3.33            1.39 - 7.94   0.031
  Ever-use DMPA                      2.84            1.40 - 5.73   0.008
  Nulliparous                        3.71            1.81 - 7.60   0.003

DMPA: depot medroxyprogesterone acetate. P value \< 0.05 indicates statistical significance.

A total of 129 women in this study continued using DMPA for at least one year, among whom 13 women had an excessive weight gain at 6 months and 116 women had less gain. The prevalence of a later excessive weight gain was 8.5% (95% CI: 3.6 - 13.4).The trend of weight changes of each individual woman with excessive weight gaining at 12 months after DMPA initiation was shown in [Figure 3](#F3){ref-type="fig"}. Nearly half of the early gainers had gained even more weight (\> 10% of their baseline weigh) at 12 months. However, only 4% of non-early gainer had a later excessive weight gain ([Fig. 1](#F1){ref-type="fig"}). Early gainers had 10-fold higher risk of further later excessive weight gain than non-early weight gainers (RR 10.71, 95% CI 3.79 - 30.26, P \< 0.001).

![The trend of weight changes of each individual woman who has an excessive weight gain at 12 months after DMPA initiation. DMPA: depot medroxyprogesterone acetate.](jocmr-11-326-g003){#F3}

Discussion {#s4}
==========

This study focused on determining the impact of DMPA use on the occurrence of an excessive weight gain because large amount of gaining might lead to overweight and obesity which can further lead to long-term health problems. We used an increasing weight of more than 5 and 10% of their baseline weight at 6 and 12 months after DMPA initiation according to a significant impact on reproductive health when 5-10% of the weight was changed \[[@R10], [@R11]\].

The overall prevalence of an excessive weight gain among adolescent girls and younger women in this study were 12.1% at 6 months after DMPA use and 8.5 % at 12 months after DMPA use, respectively. The lower prevalence in our study might be due to the difference in age, race and baseline BMI \[[@R06]-[@R08]\]. In the present study, we included only women aged 10 - 24 years and most of them were Thai and had normal BMI prior to initiating DMPA injection. However, our findings were consistent with a recent systematic review, which concluded that there were a small number of women who had weight gaining associated with progestin-only contraceptive use \[[@R9]\].

During the study, we also identified risk factors of an early excessive weight gain as the secondary objective and our data suggested that risk factors for having an early excessive weight gain were nulliparity, unmarried status, and prior DMPA use that were different from the previous reports. However, the predicting risk factors of substantial weight gain in DMPA user were difficult to identify and still inconsistent among several studies. Some previous studies reported that the difference in an excessive weight gain depended on race and ethnicities, which was more prevalent in black than in white, Hispanic, and Asian populations \[[@R06], [@R12]\]. Some study reported increased risk of excessive weight gain on DMPA use that was associated with baseline BMI or initial overweight \[[@R07], [@R10]\]. Some studies found an increasing weight during DMPA, which was related to parity \[[@R07]\]. However, some studies did not find any factors that were associated with the risk of weight gain \[[@R08]\]. However, our data suggested that an early excessive weight was related to continued excessive weight gain and can be used to predict it, which was consistent with recent reports \[[@R07], [@R13]\].

From these findings, our study supports that only a few adolescent girls and young women on DMPA suffered from an excessive weight gain associated with this contraceptive method. However, adolescent girls and younger women who had an early excessive weight gain at 6 months after DMPA use were at 10-time increased risk for continued excessive gain at 1 year, which could have negatively impacted on further health. In addition, weight gain was not a uniform finding among all women using DMPA injection. Only non-married status, nulliparity and history of DMPA ever use were associated with an increasing risk of excessive weight gain.

A limitation of the present study was its retrospective study design that could not control for numerous confounds and usually faces the problem of missing data.

Conclusions {#s4a}
-----------

In summary, the majority of adolescent girls and young women using DMPA had no excessive weight gain. The potential for excessive weight gain with DMPA use is probable for some women who were nulliparous, were in unmarried or non-in union status, and had ever used DMPA. In addition, our finding further supports that an early excessive weight at 6 months was a useful clinical predictor to identify women at risk for continued weight gaining at 1 year. Thus, early gainers should be informed about this impact and be advised for routine exercise and dietary control.
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